乌司奴单抗与TNF抑制剂在银屑病关节炎患者中的长期有效性和持续性:PsABio真实世界研究3年最终结果
PsABio为前瞻性观察性研究,纳入895例银屑病关节炎患者,随访3年,比较乌司奴单抗与TNF抑制剂的持续性和有效性。3年时两组持续用药比例相似(乌司奴单抗49.9% vs TNFi 47.8%),停药/换药风险无差异(PS校正HR 0.87,95%CI 0.68-1.11)。TNFi组达到有效性结局的比例更高,但乌司奴单抗组不良事件发生率更低。
要点
- 3年持续用药比例乌司奴单抗49.9% vs TNFi 47.8%,停药/换药风险无差异
- TNFi组达到cDAPSA LDA/缓解及MDA/VLDA的比例更高,PS校正OR的95%CI跨1
- 乌司奴单抗组不良事件发生率低于TNFi组
核心结论
- 3年时乌司奴单抗与TNF抑制剂的持续用药情况总体相当,但乌司奴单抗的不良事件发生率更低。
研究设计与样本
- PsABio(NCT02627768)为前瞻性观察性研究,纳入895例接受一线至三线乌司奴单抗或TNF抑制剂治疗的银屑病关节炎患者,每6个月评估持续性和有效性,收集3年安全性数据,采用倾向评分校正基线差异后比较两种作用机制。
主要发现
- 3年时仍使用初始治疗的患者比例:乌司奴单抗组49.9% vs TNFi组47.8%。
- 停药/换药风险的PS校正HR(95%CI)为乌司奴单抗 vs TNFi 0.87(0.68-1.11)。
- 总体人群中,cDAPSA LDA/缓解:乌司奴单抗组58.6%/31.4% vs TNFi组69.8%/45.0%;PS校正OR(95%CI)LDA为0.89(0.63-1.26),缓解为0.72(0.50-1.05)。
- MDA/VLDA:乌司奴单抗组41.4%/19.2% vs TNFi组54.2%/26.9%,PS校正OR的95%CI重叠。
- TNFi组达到有效性结局的患者比例更高;乌司奴单抗组不良事件发生率低于TNFi组。
关键数值与推荐
- 持续性:3年仍使用初始治疗比例乌司奴单抗49.9% vs TNFi 47.8%;停药/换药PS校正HR 0.87(95%CI 0.68-1.11)。
- cDAPSA LDA:乌司奴单抗58.6% vs TNFi 69.8%,PS校正OR 0.89(95%CI 0.63-1.26)。
- cDAPSA缓解:乌司奴单抗31.4% vs TNFi 45.0%,PS校正OR 0.72(95%CI 0.50-1.05)。
- MDA:乌司奴单抗41.4% vs TNFi 54.2%;VLDA:乌司奴单抗19.2% vs TNFi 26.9%,PS校正OR的95%CI重叠。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. METHODS: PsABio (NCT02627768), a prospective, observational study, followed patients with PsA prescribed first-line to third-line ustekinumab or a TNFi. Persistence and effectiveness (achievement of clinical Disease Activity for PSA (cDAPSA) low disease activity (LDA)/remission and minimal disease activity/very LDA (MDA/VLDA)) were assessed every 6 months. Safety data were collected over 3 years. Analyses to compare the modes of action were adjusted on baseline differences by propensity scores (PS). RESULTS: In 895 patients (mean age 49.8 years, 44.7% males), at 3 years, the proportion of patients still on their initial treatments was similar with ustekinumab (49.9%) and TNFi (47.8%). No difference was seen in the risk of stopping/switching; PS-adjusted hazard ratio (95% CI) for stopping/switching ustekinumab versus TNFi was 0.87 (0.68 to 1.11). In the overall population, cDAPSA LDA/remission was achieved in 58.6%/31.4% ustekinumab-treated and 69.8%/45.0% TNFi-treated patients; PS-adjusted ORs (95% CI) were 0.89 (0.63 to 1.26) for cDAPSA LDA; 0.72 (0.50 to 1.05) for remission. MDA/VLDA was achieved in 41.4%/19.2% of ustekinumab-treated and 54.2%/26.9% of TNFi-treated patients with overlapping PS-adjusted ORs. A greater percentage of TNFi-treated patients achieved effectiveness outcomes. Both treatments exhibited good long-term safety profiles, although ustekinumab-treated patients had a lower rate of adverse events (AEs) versus TNFi. CONCLUSION: At 3 years, there was generally comparable persistence after ustekinumab or TNFi treatment, but AE rates were lower with ustekinumab.
引用
- Gossec L, Siebert S, Bergmans P, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann Rheum Dis. 2022. PMID: 36600178. doi:10.1136/ard-2022-222879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。